Fireball seen as meteorite streaks through sky over Georgia and South Carolina
A fireball, or a bright meteorite, was seen across the southeastern United States on Thursday and later exploded over Georgia, creating booms heard by residents in the area, according to NASA.
The American Meteor Society said it received more than 160 reports of a fireball sighting from observers in Georgia and South Carolina at 12:25 p.m. ET. The meteor was first seen at an altitude of 48 miles above the town of Oxford, Georgia, moving southwest at 30,000 miles per hour, said Bill Cooke, a lead at NASA's Meteoroid Environment Office.
The fireball later exploded 27 miles above West Forest, Georgia, unleashing an energy of about 20 tons of TNT. Cooke said the fireball was 3 feet in diameter and weighed more than a ton (2,000 pounds).
"The resulting pressure wave propagated to the ground, creating booms heard by many in that area," Cooke said in a statement.
This NOAA satellite image, shared by NASA, shows where a meteorite streaked through the sky over Georgia. Sightings were also reported in neighboring South Carolina.
NOAA/NASA
When a space rock enters the atmosphere on its own and burns up, it's called a meteor. It's a meteorite if it survives the trip and makes contact with the ground before burning up. Those that appear especially bright are called fireballs, according to NASA.
This daylight fireball on Thursday could be a member of the Beta Taurid meteor shower, which includes meteors that are rarely seen and are typically active from late June to early July, peaking around June 25, said Robert Lunsford of the American Meteor Society.
"I would estimate that we receive reports of one daylight event per month from all over the world," Lunsford told CBS News. "I would say one out [of] every 700 fireball events involves a fireball seen during daylight hours. So these events are rare, and most people go a lifetime without seeing one."
A fireball during the evening was seen over vast sections of the eastern U.S. and parts of Canada in February 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
41 minutes ago
- Medscape
Delayed Brain Bleeds in Head Trauma Rare With Anticoagulants
TOPLINE: Delayed intracranial hemorrhage (ICH) occurred in 2% of patients with mild traumatic brain injury and a negative initial CT who were receiving anticoagulant therapy, a study found. METHODOLOGY: Researchers conducted a retrospective study of 596 patients (median age, 83 years; 46.5% men) who were receiving anticoagulant therapy and presented with mild traumatic brain injury (Glasgow Coma Scale score, ≥ 13) and a negative initial CT. Atrial fibrillation was the most frequent indication for anticoagulant therapy (84.4%), followed by deep vein thrombosis/pulmonary embolism (9.6%); 74.5% of patients were on direct oral anticoagulants (53.4% received a reduced dosage), and 25.5% were treated with vitamin K antagonists. Patients underwent a second CT scan after 24 hours of observation. The primary outcome was the incidence of delayed ICH, and secondary outcomes included the need for neurosurgical interventions and 30-day mortality. TAKEAWAY: Delayed ICH occurred in 2% of patients, with subarachnoid hemorrhage and subdural hematoma being the most common findings (five patients each). None of the patients with delayed ICH required neurosurgical intervention or died within 30 days. Patients with delayed ICH had higher rates of high-energy trauma (17% vs 1.7%; P = .044) than those with a negative second CT scan. Delayed ICH was more frequent in those receiving vitamin K antagonists than in those on direct oral anticoagulants, although the difference was not significant. Among patients with delayed ICH, 66% experienced complications during hospitalization, mainly nosocomial infections and delirium. IN PRACTICE: "[The low incidence of delayed ICH suggests that patients with minor traumatic brain injury and normal initial CT imaging] may be safely discharged without extended hospital observation, provided they have no additional risk factors," the authors wrote. SOURCE: This study was led by Jacopo Davide Giamello, Santa Croce e Carle Hospital, Cuneo, Italy. It was published online on June 11, 2025, in Injury. LIMITATIONS: This study had a retrospective, single-center design, and its findings may have been affected by misclassification bias. Data on long-term outcomes and medication adherence or anticoagulation intensity over time were missing. DISCLOSURES: This study did not receive any external funding. The authors reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
an hour ago
- Medscape
New Heart Risk Tool Reveals Hidden Ethnic Patterns
TOPLINE: The American Heart Association's Predicting Risk of Cardiovascular Disease Events (PREVENT) equations successfully identified the risk for heart problems in a group of 361,778 ethnically diverse patients. Over a mean follow-up of 8.1 years, researchers observed 22,648 cardiovascular events, with the equations showing modest variation in performance across disaggregated ethnic subgroups. METHODOLOGY: The retrospective cohort study analyzed 361,778 primary care patients aged 30-79 years across the Sutter Health system in Northern California from January 2010 to September 2023, with participants requiring at least two primary care visits during the study period. Participants were required to have several baseline data points for the PREVENT equations to evaluate, including non-high-density lipoprotein (HDL) cholesterol, systolic blood pressure, BMI, estimated glomerular filtration rate, diabetes status, and smoking status, all while being free of cardiovascular disease (CVD). Primary outcomes included identifying CVD events, defined as total CVD, atherosclerotic CVD, and heart failure, using International Classification of Diseases, Ninth and Tenth Revision codes, with a mean follow-up duration of 8.1 years. TAKEAWAY: Among Asian populations, C statistics for total CVD ranged from a C statistic of 0.79 (95% CI, 0.77-0.81) in Filipino patients to a C statistic of 0.85 (95% CI, 0.83-0.87) in Asian Indian patients, with calibration slopes generally under 1.0, except for Asian Indian participants. Hispanic subgroups showed consistent C statistics — a measure of how well a model distinguishes between two groups — between 0.80 and 0.82 for total CVD and good predictive performance. The PREVENT equations outperformed the pooled cohort equations for predicting atherosclerotic CVD across all racial and ethnic groups and subgroups. The researchers observed small differences in the performance of PREVENT equations for atherosclerotic CVD and heart failure among racial and ethnic groups and subgroups. IN PRACTICE: 'Our results show that PREVENT equations performed well in this study cohort and similarly to the original equation development and validation cohort on the discrimination measure,' the researchers reported. 'In particular, the performance was slightly better in discriminating CVD events for Asian and Hispanic participants compared to Black or White participants in the study population. The equations slightly overestimated CVD risk for all three CVD event types in Asian and most Asian subgroups and accurately predicted CVD events among Hispanic and disaggregated Hispanic subgroups.' 'As the burden of CVD and its risk factors is forecasted to increase in the coming decades alongside rapid growth of the Asian and Hispanic populations in the US, the imperative for equitable clinical CVD prevention is more urgent than ever,' wrote Nilay S. Shah, MD, MPH, of Northwestern University Feinberg School of Medicine, in Chicago, in an editorial accompanying the journal article. 'Although best practices for clinical implementation of the PREVENT cardiovascular disease risk prediction models should be further investigated, [the new study shows] that the PREVENT equations are an important step forward for Asian and Hispanic communities that until now were unseen in CVD prevention recommendations.' SOURCE: The study was led by Xiaowei Yan, PhD, MS, MPH, of the Center for Health Systems Research at Sutter Health in Walnut Creek, California. It was published online on June 25 in JAMA Cardiology. LIMITATIONS: Despite disaggregation of Asian and Hispanic subgroups, the researchers were unable to fully examine other disaggregated groups due to small sample sizes. As a study based on data from a healthcare system, the population may be biased toward less healthy individuals compared to the general population. Almost half of eligible patients had incomplete data and were excluded from the analysis, potentially introducing selection bias. DISCLOSURES: The study received funding from the National Heart, Lung, and Blood Institute; the American Heart Association/Harold Amos Medical Faculty Development program; and the Doris Duke Foundation, as well as consulting fees from multiple organizations including Novartis, Novo Nordisk, Esperion Therapeutics, and others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Hugging Face Co-Founder Challenges AI Optimists: 'Models Can't Ask Original Scientific Questions'
Thomas Wolf, co-founder and chief science officer at Hugging Face, has cast doubt on the belief that current artificial intelligence systems will lead to major scientific breakthroughs. Wolf told Fortune that today's large language models, or LLMs, excel at providing answers but fall short when it comes to formulating original questions. 'In science, asking the question is the hard part,' he said. 'Once the question is asked, often the answer is quite obvious, but the tough part is really asking the question, and models are very bad at asking great questions.' Don't Miss: GoSun's breakthrough rooftop EV charger already has 2,000+ units reserved — become an investor in this $41.3M clean energy brand today. Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. Wolf's comments were in response to a blog post by Anthropic CEO Dario Amodei, who argues that artificial intelligence could compress a century's worth of scientific breakthroughs into just a few years. Wolf said he initially found the post compelling but became skeptical after rereading. 'It was saying AI is going to solve cancer, and it's going to solve mental health problems—it's going to even bring peace into the world. But then I read it again and realized there's something that sounds very wrong about it, and I don't believe that,' he told Fortune. San Francisco-based Anthropic is backed by tech giants, including Inc. (NASDAQ:AMZN) and Alphabet Inc. (NASDAQ:GOOG, GOOGL)), and is also known for its Claude family of AI models. For Wolf, the core issue lies in how LLMs are trained. In another blog post, Wolf argues that today's AI systems are built to predict likely outcomes, act as "yes-men on servers," capable of mimicking human responses but incapable of challenging assumptions or generating original ideas. "To create an Einstein in a data center, we don't just need a system that knows all the answers, but rather one that can ask questions nobody else has thought of or dared to ask," Wolf wrote. He cited that real scientific progress often comes from paradigm shifts—like Copernicus proposing heliocentrism or the invention of CRISPR-based gene editing—rather than from answering existing questions. Trending: This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, with minimum investments as low as $100. Wolf also questioned how AI performance is measured today. In his blog post, he pointed to benchmarks like Humanity's Last Exam or Frontier Math, which test how well AI models can answer complex but well-defined questions. "These are exactly the kinds of exams where I excelled," Wolf wrote, referencing his academic background. "But real scientific breakthroughs come not from answering known questions, but from asking challenging new ones and questioning previous ideas." He argued that AI needs to demonstrate the ability to challenge its training data, take counterfactual approaches, and identify new research directions from incomplete information. Using the board game Go as an analogy, Wolf said the landmark 2016 victory of DeepMind's AlphaGo over world champions made headlines but was not revolutionary. "Move 37, while impressive, is still essentially a straight-A student answer to the question posed by the rules of the game of Go," he wrote in his blog. "An Einstein-level breakthrough in Go would involve inventing the rules of Go itself." Hugging Face is a prominent open-source platform in the AI community, known for its collaborative development of open-source machine learning models and tools. The company is backed by investors including Sequoia Capital and Lux Capital, and it plays a leading role in developing transparent and accessible AI systems. Wolf concluded that while current models are useful as assistants, true scientific progress requires a different kind of intelligence—one that can formulate disruptive questions rather than repeat what is already known. See Next: $100k in assets? Maximize your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $100. UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? (AMZN): Free Stock Analysis Report ALPHABET (GOOG): Free Stock Analysis Report This article Hugging Face Co-Founder Challenges AI Optimists: 'Models Can't Ask Original Scientific Questions' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
